Find out all about your favorite commercial!

TV spots

TV commercials Prevnar 13

Prevnar 13 TV Spot, 'Alto riesgo'
Prevnar 13 TV Spot, 'Don't Miss Out on Life: Wedding'
Prevnar 13 TV Spot, 'Don't Miss Out on Life'
Prevnar 13 TV Spot, 'Increased Risk'
Prevnar 13 TV Spot, 'One Step'
Prevnar 13 TV Spot, 'Prevención'
Prevnar 13 TV Spot, 'Prevention'
Advertisers

Advertisers of commercials featuring Prevnar 13

Prevnar 13 tv commercials
Prevnar 13

Prevnar 13 is a pneumococcal conjugate vaccine developed by the company Pfizer. It is designed to protect against infections caused by 13 different strains of Streptococcus pneumoniae, a bacterium res...

Actors

Actors who starred in Prevnar 13 commercials

Eric Goode photo
Robert Shoofey photo
Rodd Houston photo
Agenices

Agencies worked with Prevnar 13

Prevnar 13 tv commercials
RTC Relationship Marketing
Collaborated with Prevnar 13

What is Prevnar 13?

Prevnar 13 tv commercials

Prevnar 13 is a pneumococcal conjugate vaccine that was licensed by the US Food and Drug Administration (FDA) in 2010 for the prevention of pneumococcal disease. It contains 13 types of Streptococcus pneumoniae bacteria, the most common cause of invasive pneumococcal disease. Prevnar 13 is used in children and adults and is recommended for routine vaccination of all children under the age of 2 years, as well as for individuals aged 2-64 years who are at high risk of pneumococcal disease.

In addition to Prevnar 13, there are other pneumococcal vaccines available, including a 23-valent pneumococcal polysaccharide vaccine (PPSV23). Prevnar 13 is a newer vaccine and provides coverage for different strains of pneumococcal bacteria than PPSV23. In 2022, a 15-valent pneumococcal conjugate vaccine (PCV15; Vaxneuvance) was also approved by the FDA for use in adults and is expected to replace Prevnar 13 over time.

Like all vaccines , Prevnar 13 can cause side effects, although most are mild and go away on their own. Common side effects include redness, swelling, and tenderness at the injection site, as well as fever, chills, and headache. More serious side effects, such as severe allergic reactions and Guillain-Barré syndrome, are rare.

Overall, Prevnar 13 is an important tool for preventing pneumococcal disease and its complications, including meningitis, pneumonia, and sepsis, particularly in high-risk populations such as young children, older adults, and individuals with certain medical conditions. Consult with your healthcare provider if you have any questions about Prevnar 13 or any other vaccines.

Frequently Asked Questions about prevnar 13

Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae. It is also used to protect adults and the elderly against invasive disease and pneumonia caused by S.

PCV20 (Prevnar20®) is a sterile suspension of saccharides from 20 serotypes of S. pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) individually linked to a nontoxic variant of diphtheria toxin known as CRM197.

Prevnar 13 was approved for use in the European Union in December 2009. In February 2010, Prevnar 13 was approved in the United States to replace Prevnar (PCV7), the pneumococcal 7-valent conjugate vaccine (PCV7).

About Prevnar 13 Prevnar 13 was first introduced for use in infants and young children in December 2009 in Europe and in February 2010 in the U.S., and it is now approved for such use in nearly 120 countries worldwide.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age. a Dose 1 may be given as early as 6 weeks of age. b The recommended dosing interval is 4 to 8 weeks. c The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age. Dose 1 may be given as early as 6 weeks of age. The recommended dosing interval is 4 to 8 weeks. The fourth dose should be administered at approximately 12–15 months of age, and at least 2 months after the third dose.

PREVNAR® 13 (pneumococcal 13-valent conjugate vaccine - diphtheria CRM197 protein) | Pfizer Medical Information - US.

Pfizer Canada PREVNAR 13 (pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) | Pfizer Canada.

PREVNAR® 13 (pneumococcal 13-valent conjugate vaccine - diphtheria CRM197 protein) | Pfizer Medical Information - US.

PCV vaccines are recommended to be given first because this sequence provides the best immune response to both PCV and PPSV23 vaccines.

Active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children 6 years through 17 years of age (prior to the 18th birthday). Active immunization for the prevention of pneumonia and invasive disease caused by S.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12-15 months of age. a Dose 1 may be given as early as 6 weeks of age. b The recommended dosing interval is 4 to 8 weeks.

Yes. If immunization with Prevnar 13 is being considered, the National Advisory Committee on Immunization (NACI) recommends administration of Prevnar 13 at least one year after any previous dose of PNEU-P-23 in immunocompetent adults aged 65 years and older.

2.6 Vaccination Schedule for Adults 18 Years of Age and Older. Prevnar 13 is administered as a single dose.

People who need a pneumonia vaccine should get both shots: first, the PCV13 shot and then the PPSV23 shot a year or more later. For most people, one of each shot should be enough to protect them for their entire lives. Sometimes, you may need a booster shot.

Because PCV13-type disease is at historically low levels among adults ≥65 years and most pneumococcal disease among these adults is due to non-PCV13 serotypes, ACIP no longer recommends their routine vaccination with PCV13.

Goods

Other goods

Garnier (Hair Care) Nutrisse Maximum Lightening Creme logo
Express Sequin Mock Neck Mini Dress logo
Express Womens Embellished Faux Button Up Cardigan logo
Express Mens Wool-Blend Sherpa Collar Deck Jacket logo
Express Womens Embellished V-Neck Puff Sleeve Sweater logo
Unisom Liquid Night Time Sleep-Aid logo
101 Studios The Current War logo
Dannon Light & Fit Greek Strawberry logo
Dannon Light & Fit Greek Banana Cream logo
Dannon Light & Fit Greek Blueberry logo
Dannon Light & Fit Cherry logo
Dannon Light & Fit Key Lime Greek Nonfat Yogurt logo